Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115243 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Sohaila A Shoala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt; Department of Pharm…. Hauptthemen laut MEDLINE: Chitosan, Hyaluronan Receptors, Breast Neoplasms, Hyaluronic Acid. Die Arbeit nennt 143 Literaturangaben.
Abstract (Originalsprache)
Andrographolide (AG) has been reported for its anticancer activity. However, it is classified as a class IV in the biopharmaceutics classification system (BCS). Therefore, AG possesses low bioavailability due to its low solubility and permeability. In this study, hyaluronic acid-coated chitosan nanoparticles (Hyalo-CS-NPs) were formulated to enhance AG delivery and allow the active targeting of CD44 receptors overexpressed on breast cancer cells. Results showed optimized AG-Hyalo-CS-NPs with a size of 388.2 ± 1.41 nm, a zeta potential of -25.7 ± 1.58 mV, and an entrapment efficiency of 95.3%±1.01%. In vitro release profile revealed a sustained pH-responsive release from coated and uncoated CS-NPs with greater AG release under acidic conditions that mimic the tumor microenvironment. The MTT assay demonstrated the sharpest decline in the MCF-7 cell viability. Moreover, flow cytometry studies illustrated a significant apoptosis compared to uncoated nanoparticles and AG suspension. In addition, biochemical marker evaluation showed upregulating of the pro-apoptotic protein Bax and downregulating of Bcl-2, HER2, and Cyclin D1, confirming the underlying mechanism of the anticancer activity. Finally, confocal imaging showed higher intracellular uptake from coated and uncoated CS-NPs by 2.2-fold and 1.85-fold, respectively. In conclusion, AG-Hyalo-CS-NPs is a smart, targeted nanoplatform that improves AG anticancer efficacy in breast cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt; Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
- Department of Biochemistry, Division of Clinical and Biological Sciences, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. Electronic address: manal.elsheikh@pharm.dmu.edu.eg.
Zitieren
APA
Shoala, S. A., Abbas, H., Elbedaiwy, H. M., Shamaa, M. M., & Elsheikh, M. A. (2026). Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115243
Vancouver
Shoala SA, Abbas H, Elbedaiwy HM, Shamaa MM, Elsheikh MA. Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115243
BibTeX
@article{Shoala2026,
author = {Shoala, Sohaila A and Abbas, Haidy and Elbedaiwy, Heba M and Shamaa, Marium M and Elsheikh, Manal A},
title = {Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115243}
}
EUVIMED